Research programme: therapeutic monoclonal antibodies - Merck/XOMA

Drug Profile

Research programme: therapeutic monoclonal antibodies - Merck/XOMA

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Schering-Plough; XOMA
  • Developer XOMA
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 23 Mar 2010 Preclinical development is ongoing
  • 17 Jan 2007 Schering-Plough exercises its right to additional discovery and development programmes with XOMA
  • 30 May 2006 Preclinical trials in Undefined in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top